Novo Nordisk launches initiative for access to its legal semaglutide

Novo Nordisk (NVO) announced a series of initiatives to support patient access to authentic, FDA-approved Wegovy – semaglutide – injection 2.4 mg. as the FDA grace period for mass compounding of “semaglutide” expires. A one-time offer for self-paying patients new to Wegovy is now available for a limited time, through June 30. This one-time offer is intended to help patients who have previously been prescribed unapproved or illicit “semaglutide” drugs and are seeking access to FDA-approved Wegovy. Novo Nordisk is offering self-paying patients who are new to Wegovy their first month of medicine for $199 through June 30. For subsequent months, self-pay patients will pay $499 per month. The company continues to invest in actively correcting misinformation and educating communities about the risks of knockoff “semaglutide”. The campaign emphasizes the importance of using FDA-approved treatments and directs patients to trusted resources. Now that the FDA’s grace period has ended, any entity that mass produces or sells knockoff “semaglutide” is breaking the law and putting patient safety at risk. Nearly all “semaglutide” used in compounding is manufactured by Chinese and other foreign suppliers. The FDA has never authorized or approved the manufacturing processes used by any of these foreign suppliers, nor has the FDA reviewed or authorized the quality of the “semaglutide” they produce. Novo Nordisk will continue pursuing legal action to protect patients from the risks posed by unapproved knockoff drugs and foreign illicit active pharmaceutical ingredients.